<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sevelamer: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sevelamer: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sevelamer: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11045" href="/d/html/11045.html" rel="external">see "Sevelamer: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12975" href="/d/html/12975.html" rel="external">see "Sevelamer: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220777"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Renagel [DSC];</li>
<li>Renvela</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868226"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Sevelamer;</li>
<li>Renagel;</li>
<li>Renvela</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F220795"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphate Binder</li></ul></div>
<div class="block doa drugH1Div" id="F220780"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Sevelamer carbonate and sevelamer hydrochloride are dosed the same on a milligram-to-milligram basis; when switching between products, use the same dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="260f20d5-597c-46c0-b39a-7bd210352f76">Hyperphosphatemia in chronic kidney disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease, treatment:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Use in combination with dietary phosphate restriction (KDIGO 2017). Sevelamer <b>carbonate</b> is preferred in patients with nondialysis-dependent chronic kidney disease or metabolic acidosis due to risk of metabolic acidosis with sevelamer <b>hydrochloride</b> (Quarles 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b>Initial: Based on serum phosphorous levels:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;5.5 to &lt;7.5 mg/dL: 800 mg 3 times daily with meals.</p>
<p style="text-indent:-2em;margin-left:4em;">7.5 to &lt;9 mg/dL: 1,200 to 1,600 mg 3 times daily with meals.</p>
<p style="text-indent:-2em;margin-left:4em;">≥9 mg/dL: 1,600 mg 3 times daily with meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Dosage adjustment: Increase or decrease dose by 400 to 800 mg per meal at 2-week intervals as needed to obtain targeted serum phosphorus concentrations; usual dosage range: 800 to 2,400 mg 3 times daily (Quarles 2022; manufacturer’s labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990338"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987695"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F220781"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F5265838"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12975" href="/d/html/12975.html" rel="external">see "Sevelamer: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations</b>: Phosphate binding capacity: Sevelamer hydrochloride 400 mg binds ~32 mg of phosphate; 800 mg binds ~64 mg of phosphate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDOQI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDOQI.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fa25feb-0bb2-4a92-9cc4-acd80100a89e">Hyperphosphatemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sevelamer</i>
<i> carbonate (Renvela): </i>Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients not taking a phosphate binder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28900759','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28900759','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥0.75 to &lt;1.2 m<sup>2</sup>: Oral: 800 mg 3 times daily with meals; titrate as needed by 400 mg per dose at 2-week intervals.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥1.2 m<sup>2</sup>: Oral: 1,600 mg 3 times daily with meals; titrate as needed by 800 mg per dose at 2-week intervals.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment when switching from calcium acetate to sevelamer carbonate:</i> 667 mg of calcium acetate is equivalent to ~800 mg of sevelamer; conversion based on dose per meal:</p>
<p style="text-indent:-2em;margin-left:8em;">Calcium acetate 667 mg: Convert to 800 mg sevelamer carbonate.</p>
<p style="text-indent:-2em;margin-left:8em;">Calcium acetate 1,334 mg: Convert to 1,600 mg sevelamer carbonate.</p>
<p style="text-indent:-2em;margin-left:8em;">Calcium acetate 2,001 mg: Convert to 2,400 mg sevelamer carbonate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sevelamer hydrochloride (Renagel):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥10 months and Children &lt;2 years: Very limited data: Oral: Mean final dose of 140 ± 86 mg/kg/day (5.38 ± 3.24 <b>g</b>/day) was reported in a small trial (n=18; age range: 10 months to 18 years) to achieve the targeted serum phosphorus level. Initial dosing was based upon prior phosphate binder dose and serum phosphorus concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16564940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16564940'])">Ref</a></span>). In a case report of a 19-month-old, an initial dose of 100 mg/kg/day divided every 8 hours with titration up to 130 mg/kg/day was reported to effectively lower serum phosphorus levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16503722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16503722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: Limited data available: Oral: Initial dose: 400 or 800 mg 3 times daily administered with meals; titrate at monthly intervals in 1,200 mg/day increments (ie, 400 mg at each meal) to target phosphorus level; final mean range: 140 to 163 mg/kg/day (5.38 to 6.7 <b>g</b>/day); dosing based on experience in 46 patients; prior or final comparative calcium salt phosphate-binder dose: 4 ± 3 <b>g</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20020207','lexi-content-ref-14586677','lexi-content-ref-16564940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20020207','lexi-content-ref-14586677','lexi-content-ref-16564940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment when switching from calcium acetate to sevelamer hydrochloride:</i> 667 mg of calcium acetate is equivalent to ~800 mg of sevelamer; conversion based on dose per meal.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8dd690ba-d623-4c72-a693-89884db62c3d">Renal failure; pretreatment of oral and enteral nutrition formula, expressed breast milk, or cow's milk to decrease phosphate load</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal failure; pretreatment of oral and enteral nutrition formula, expressed breast milk, or cow's milk to decrease phosphate load:</b> Limited data available: Infants and Children:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expressed breast milk, infant/enteral formula, or cow's milk: </i>Sevelamer hydrochloride or sevelamer carbonate: Add 800 mg (tablets or powder) to up to 400 mL of breast milk or 100 mL of infant formula, tube feeding, and cow's milk; after the addition of sevelamer, allow to sit for 10 minutes, then decant liquid for feed and leave the precipitate at the bottom. Reported experience has shown a decrease in phosphate of &gt;85% in breast milk, 42% in cow's milk, 48% in tube feeding, and 68% in infant formula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19231749','lexi-content-ref-23636435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19231749','lexi-content-ref-23636435'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192833"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment is unnecessary as sevelamer is indicated for use in chronic kidney disease.</p></div>
<div class="block dohp drugH1Div" id="F51192834"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F220752"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Metabolic acidosis (children: 34% [Pieper 2006]; adults: Frequency not defined)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (19%), dyspepsia (16%), nausea (20%), vomiting (22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Abdominal pain (9%), constipation (8%), flatulence (8%), peritonitis (peritoneal dialysis: 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis, dysphagia, fecal impaction, gastric ulcer with hemorrhage, gastrointestinal necrosis, gastrointestinal ulcer, intestinal obstruction, intestinal perforation</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F220765"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sevelamer or any component of the formulation; bowel obstruction</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypophosphatemia; active mucosal injury (eg, necrosis, perforation, ulcerative colitis, GI bleeding)</p></div>
<div class="block war drugH1Div" id="F220749"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Bowel obstruction, bleeding GI ulcers, colitis, ulceration, necrosis, and perforation have been reported; consider discontinuation of therapy in patients who develop severe symptoms. Dysphagia and esophageal tablet retention have also been reported with the tablet formulation; consider change to suspension formulation in patients with a history of swallowing disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders including dysphagia, swallowing disorders, severe gastrointestinal motility disorders (including severe constipation), or major gastrointestinal surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamins: May cause reductions in vitamin D, E, K, or folic acid absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tablets: Should not be taken apart or chewed; broken or crushed tablets will rapidly expand in water/saliva and may be a choking hazard.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878629"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In a trial conducted in pediatric patients (n=18; age range: 10 months to 18 years), an increase in metabolic acidosis was noted in patients receiving sevelamer hydrochloride (incidence: 34.4%) (Pieper 2006); in another pediatric trial (n=17; age range: 2 to 18 years), no untoward effects were reported (Mahdavi 2003). Patients should be closely monitored.</p></div>
<div class="block foc drugH1Div" id="F220760"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renvela: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea) [citrus flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renvela: 800 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 800 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renagel: 800 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg, 800 mg</p></div>
<div class="block geq drugH1Div" id="F220745"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F220767"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Renvela Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.8 g (per each): $21.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.4 g (per each): $21.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Sevelamer Carbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.8 g (per each): $11.35 - $19.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.4 g (per each): $11.35 - $19.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Renvela Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $7.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sevelamer Carbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $0.22 - $6.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sevelamer HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $4.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $7.20 - $8.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868227"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renvela: 0.8 g (90 ea); 2.4 g (90 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renvela: 800 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 800 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renagel: 800 mg</p></div>
<div class="block adm drugH1Div" id="F220762"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for oral suspension: May prepare an oral suspension in water using the directed amount of water appropriate for the packet size <b>or</b> may premix the entire content of the packet with a small amount of food or beverage (do not heat or add to heated foods or liquids).</p>
<p style="text-indent:-2em;margin-left:2em;">Preparations should be consumed immediately or within 30 minutes. Oral suspension in water may need to be resuspended immediately before drinking.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Swallow whole; do not crush, chew, or break.</p></div>
<div class="block admp drugH1Div" id="F52613850"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with meals. Consider separating administration of oral medications from sevelamer when reduced bioavailability would significantly affect the concomitant medication's safety or efficacy (eg, cyclosporine, tacrolimus, levothyroxine); duration of separation varies based on absorption characteristics and whether it is an immediate-release or extended-release product; monitor clinical response and/or blood concentrations of concomitant medications.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Swallow tablets whole; do not break, chew, or crush; contents will expand with water.</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for oral suspension (sevelamer carbonate): Administer reconstituted oral suspension immediately or within 30 minutes; oral suspension may need to be resuspended immediately before drinking. Alternatively, the powder contents of the packet may be premixed with a small amount of food or beverage and consumed immediately (or within 30 minutes) as part of a meal. Do not heat or add to heated food or liquid.</p></div>
<div class="block use drugH1Div" id="F220761"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease, </b>
<b>treatment</b>: Control of serum phosphorous in patients with chronic kidney disease (CKD) on hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Based on the Kidney Disease: Improving Global Outcome guideline update for the diagnosis, evaluation, prevention, and treatment of CKD–mineral and bone disorder (CKD-MBD), sevelamer may also be used to control serum phosphorous in patients with grades 3 to 5 CKD not on hemodialysis who exhibit progressively or persistently elevated serum phosphate levels (KDIGO 2017).</p></div>
<div class="block mst drugH1Div" id="F220802"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renagel may be confused with Reglan, Regonol, Renvela </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renvela may be confused with Reglan, Regonol, Renagel</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sevelamer may be confused with Savella</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Renagel [US, Canada, and multiple international markets] may be confused with Remegel brand name for aluminium hydroxide and magnesium carbonate [Netherlands] and for calcium carbonate [Hungary, Great Britain and Ireland] and with Remegel Wind Relief brand name for calcium carbonate and simethicone [Great Britain]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300038"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F220754"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Sevelamer may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholic Acid: Sevelamer may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any bile acid-binding products, such as sevelamer, to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): Sevelamer may decrease the serum concentration of Ciprofloxacin (Systemic).  Management: Administer ciprofloxacin at least 2 hours before or 6 hours after sevelamer administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Sevelamer may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine.  Management: Separate administration of sevelamer and levothyroxine by at least 4 hours to decrease the risk of a significant interaction. Monitor clinical and laboratory response to levothyroxine closely when used together with sevelamer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate.  Management: Administer mycophenolate at least 2 hours prior to sevelamer administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Sevelamer may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of sevelamer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Sevelamer may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F13851538"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">May cause reductions in vitamin D, E, K, or folic acid absorption. Management: Must be administered with meals. Consider vitamin supplementation.</p></div>
<div class="block pri drugH1Div" id="F220768"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sevelamer is not absorbed systemically; however, it may reduce maternal absorption of fat soluble vitamins and folic acid; supplementation may be needed.</p></div>
<div class="block brc drugH1Div" id="F220769"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sevelamer is not absorbed systemically and breastfeeding is not expected to cause exposure to a breastfeeding infant.</p>
<p style="text-indent:-2em;margin-left:2em;">Sevelamer may reduce maternal absorption of fat soluble vitamins and folic acid; supplementation may be needed.</p></div>
<div class="block dic drugH1Div" id="F1044875"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with meals. Reduced levels of folic acid, and vitamins D, E, and K may occur; most hemodialysis patients in clinical trials received vitamin supplementation. </p></div>
<div class="block mop drugH1Div" id="F220758"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Serum chemistries, including bicarbonate and chloride</p>
<p style="text-indent:-2em;margin-left:2em;">Serum calcium, phosphorus, and parathyroid hormone (PTH): Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of chronic kidney disease (CKD), and the use of treatments for chronic kidney disease-mineral and bone disorder (CKD-MBD) (KDIGO 2017):</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G3a to G3b: Serum calcium and phosphate: Every 6 to 12 months; PTH: Frequency based on baseline level and progression of CKD</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G4: Serum calcium and phosphate: Every 3 to 6 months; PTH: Every 6 to 12 months</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G5 and G5D: Serum calcium and phosphate: Every 1 to 3 months; PTH: Every 3 to 6 months</p>
<p style="text-indent:-2em;margin-left:2em;">Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3 to 12 months depending on CKD severity</p></div>
<div class="block rer drugH1Div" id="F13203338"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to the complexity and interdependency of the laboratory parameters used for therapeutic decisions in chronic kidney disease-mineral and bone disorder (CKD-MBD) patients, serial assessments of phosphate, calcium, and parathyroid hormone (PTH) levels should be considered together (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium (total): Normal range: Adults: 8.5 to 10.5 mg/dL (2.12 to 2.62 mmol/L) (IOM 2011). Avoid hypercalcemia for CKD stages G3a to G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L). Lower elevated phosphorus levels toward the normal range for CKD stages G3a to G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">PTH:</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G3a to G5: Optimal PTH level is unknown; evaluate patients with progressively elevated intact PTH levels or if levels are consistently above the normal range (assay-dependent) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Dialysis patients: Maintain iPTH within 2 to 9 times the upper limit of normal for the assay used (KDIGO 2017).</p></div>
<div class="block pha drugH1Div" id="F220748"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sevelamer (a polymeric compound) binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations.</p></div>
<div class="block phk drugH1Div" id="F220764"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Reduction in serum phosphorus has been demonstrated after 1-2 weeks (Burke 1997; Chertow 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not systemically absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038827"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Foseva | Postiline | Renvela | Sevelamer sandoz | Vemer</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer ratiopharm | Sevelamer sandoz | Sevelamercarbonat medice | Sevelamercarbonat stada | Sevelamercarbonat zentiva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Sevelamer apotex | Sevelamer lupin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Inophos | Renophos | Renvela | Sevel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sevelamer carbonate heaton</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de sevelamer | Foslamer | Hemosev | Renagel | Sevclot</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamercarbonate salmon pharma</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Renvela</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nuo wei le</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dilutase | Foslamer | Ranlat | Renagel | Renvela | Sertrex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate heaton | Sevelamer carbonate mylan | Sevemed</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate al | Sevelamercarb mylan | Sevelamercarbonat al | Sevelamercarbonat hexal | Sevelamercarbonat ratiopharm | Sevelamercarbonat stada | Sevelamercarbonat winthrop | Sevelamercarbonat zentiva | Sevemed</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Foseal | Ranlat | Renvela</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fosanid | Ranlat | Renvela</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer auxilia</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Reguphose | Renagel | Sevelam</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carbonato de sevelamero zentiva | Fosquel | Renagel | Renvela | Sevelamero aristo | Sevelamero kern | Sevelamero kern pharma | Sevelamero mylan | Sevelamero ratiopharm | Sevelamero sandoz | Sevelamero stada | Sevelamero teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Foseal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer avansor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Chlorhydrate de sevelamer waymade | Renagel | Renvela | Sevelamer carbonate arrow | Sevelamer carbonate Biogaran | Sevelamer Carbonate EG | Sevelamer carbonate mylan | Sevelamer carbonate sandoz | Sevelamer carbonate teva | Tasermity</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate Zentiva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer/demo | Sevelamer/faran | Sevelamer/mylan | Sevelamer/sandoz</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer sandoz</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate Zentiva | Sevelamer mensana pharma</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fosbin | Renvela</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate rowex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Renagel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acutrol | Biosev | Biosev c | Famvila | Foschek S | Foseal | Foseal c | Lexorus | Phoscut | Renvela | Selbo | Sevaco3 | Sevalac | Sevcar | Sevcept | Sevelar | Sevhold | Sevlaren | Sevlasure | Sevlogen | Sevocip | Sevpos | Sevtreat | Sivel | Svelam | Velacar | Zynacar | Zynagel</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Sevelamer</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer aurobindo | Sevelamer doc | Sevelamer doc generici | Sevelamer eg | Sevelamer mylan | Sevelamer sandoz | Sevelamer sandoz gmbh</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Phosblock | Renagel</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Foseal | Selaglob | Sevcar | Sevlaren</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Invela | Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Renvela</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Foseal | Renagel | Renvela | Sevelamer carbonate arrow</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate sandoz</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Coat aprid | Renagel | Renvela | Rifosar | Rifosar pos | Sevelamero</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cavsamir | Renvela</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelameercarbonaat Aurobindo | Sevelameercarbonaat sandoz | Sevelameerhydrochloride waymade | Sevelamer mylan | Tasermity</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer mylan | Sevelamer sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Renagel</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Foseal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Corvelam | Fosbind | Renvela | Sevelamer</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Biosev | Genovel | Lamer | Neosev | Neovel | Renalamer | Renamer | Renvela | Selam | Sevelawin | Velamer | Velanef | Wenovel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevemed</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Renagel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamero mylan | Sevelamero teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Captaphos | Ranlat | Sevelamer eposino | Sevelamer prosalud | Sevelamer tuteur | Sevelamers ems</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Carbonat de sevelamer heaton | Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Selamerex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renomer | Renvela</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer 2care4 | Sevelamer carbonate Zentiva | Sevelamer Ebb | Sevelamer mylan | Sevelamer sandoz | Sevelamer teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Renvela</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer Lek | Sevelamer teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer carbonate heaton | Sevelamer carbonate mylan | Sevelamer carbonate sandoz | Sevelamer carbonate Zentiva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Kavolred | Renvela</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lameris | Perfose | Renadin | Renagel | Renalamer | Renalamer co3 | Sevaren | Terolam | Velarix</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nophos | P zero | Renagel | Renvela</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela | Sevelamer vista</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Folemax | Foslamer | Ranlat | Renvela</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Sevla</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Renagel | Renvela</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9269642">
<a name="9269642"></a>Burke SK, Slatopolsky EA, and Goldberg DI. RenaGel, a Novel Calcium- and Aluminium-Free Phosphate Binder, Inhibits Phosphate Absorption in Normal Volunteers. <i>Nephrol Dial Transplant</i>. 1997;12(8):1640-1644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/9269642/pubmed" id="9269642" target="_blank">9269642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9002531">
<a name="9002531"></a>Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine Hydrochloride] (RenaGel): A Noncalcemic Phosphate Binder for the Treatment of Hyperphosphatemia in Chronic Renal Failure. <i>Am J Kidney Dis</i>. 1997;29(1):66-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/9002531/pubmed" id="9002531" target="_blank">9002531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28900759">
<a name="28900759"></a>Fathallah-Shaykh S, Drozdz D, Flynn J, et al. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. <i>Pediatr Nephrol</i>. 2018;33(2):325-333. doi:10.1007/s00467-017-3787-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/28900759/pubmed" id="28900759" target="_blank">28900759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20020207">
<a name="20020207"></a>Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. <i>Int Urol Nephrol</i>. 2010;42(4):1055-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/20020207/pubmed" id="20020207" target="_blank">20020207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). <i>Kidney Int</i>. 2017;7(suppl 1):1-59. doi:10.1016/j.kisu.2017.04.001</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2">
<a name="KDIGO.2"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14586677">
<a name="14586677"></a>Mahdavi H, Kuizon BD, Gales B, et al. Sevelamer Hydrochloride: An Effective Phosphate Binder in Dialyzed Children. <i>Pediatr Nephrol</i>. 2003;18(12):1260-1264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/14586677/pubmed" id="14586677" target="_blank">14586677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.1">
<a name="KDOQI.1"></a>National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46:S1-S122.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19231749">
<a name="19231749"></a>National Kidney Foundation. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. <i>Am J Kidney Dis</i>. 2009;53:S1-S124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/19231749/pubmed" id="19231749" target="_blank">19231749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16564940">
<a name="16564940"></a>Pieper AK, Haffner D, Hoppe B, et al. A Randomized Crossover Trial Comparing Sevelamer With Calcium Acetate in Children With CKD. <i>Am J Kid Dis</i>. 2006;47(4):625-635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/16564940/pubmed" id="16564940" target="_blank">16564940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berkoben.1">
<a name="Berkoben.1"></a>Quarles LD. Management of hyperphosphatemia in adults with chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636435">
<a name="23636435"></a>Raaijmakers R, Houkes LM, Schröder CH, et al. Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate. <i>Perit Dial Int</i>. 2013;33(5):565-572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/23636435/pubmed" id="23636435" target="_blank">23636435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renagel.1">
<a name="Renagel.1"></a>Renagel (sevelamer hydrochloride) [prescribing information]. Cambridge, MA: Genzyme Corp; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renagel.2">
<a name="Renagel.2"></a>Renagel (sevelamer hydrochloride) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renvela.1">
<a name="Renvela.1"></a>Renvela (sevelamer carbonate) [prescribing information]. Cambridge, MA: Genzyme Corp; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renvela.2">
<a name="Renvela.2"></a>Renvela (sevelamer carbonate) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sevelamer.1">
<a name="Sevelamer.1"></a>Sevelamer [prescribing information]. Mahwah, NJ: Glenmark Pharmaceuticals Inc USA; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16503722">
<a name="16503722"></a>Storms LE, Chicella MF, Dice JE. Sevelamer Therapy for Pediatric End-Stage Renal Disease. <i>Pharmacotherapy</i>. 2006;26(3):410-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/16503722/pubmed" id="16503722" target="_blank">16503722</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10261 Version 372.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
